Etelcalcetide information

Etelcalcetide
Clinical data
Trade names	Parsabiv
Other names	Velcalcetide, telcalcetide, AMG-416, KAI-4169, ONO-5163
AHFS/Drugs.com	UK Drug Information
License data	EU EMA: by INN;
Routes of; administration	Intravenous injection
ATC code	H05BX04 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Elimination half-life	3–5 days in dialysis patients
Excretion	60% in dialysate, 7% in urine and faeces
Identifiers
	IUPAC name (6R,9R,12R,15R,18R,21R,24S,29R)-24-Acetamido-1,29-diamino-12,15,18-tris(3-carbamimidamidopropyl)-6-carbamoyl-1-imino-9,21-dimethyl-8,11,14,17,20,23-hexaoxo-26,27-dithia-2,7,10,13,16,19,22-heptaazatria contan-30-oic acid;
CAS Number	1262780-97-1;
PubChem CID	71511839;
ChemSpider	32697932;
UNII	60ME133FJB;
KEGG	D10676; as salt: D10677;
CompTox Dashboard (EPA)	DTXSID70155132 ;
Chemical and physical data
Formula	C38H73N21O10S2
Molar mass	1048.26 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C;
	InChI InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1; Key:ANIAZGVDEUQPRI-ZJQCGQFWSA-N;

Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.^[1]^[2] Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland.^[1] Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.^[3]^[4]

^ ^a ^b "Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)"
^ Martin KJ, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P, Peacock M (February 2014). "Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects". Nephrology, Dialysis, Transplantation. 29 (2): 385–92. doi:10.1093/ndt/gft417. PMC 3910343. PMID 24235081.
^ "Parsabiv New FDA Drug Approval | CenterWatch". www.centerwatch.com. Retrieved 2017-10-30.
^ Blair HA (December 2016). "Etelcalcetide: First Global Approval". Drugs. 76 (18): 1787–1792. doi:10.1007/s40265-016-0671-3. PMID 27900648. S2CID 45000617.

[amgen-1] "Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)"

[2] Martin KJ, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P, Peacock M (February 2014). "Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects". Nephrology, Dialysis, Transplantation. 29 (2): 385–92. doi:10.1093/ndt/gft417. PMC 3910343. PMID 24235081.

[3] "Parsabiv New FDA Drug Approval | CenterWatch". www.centerwatch.com. Retrieved 2017-10-30.

[:1-4] Blair HA (December 2016). "Etelcalcetide: First Global Approval". Drugs. 76 (18): 1787–1792. doi:10.1007/s40265-016-0671-3. PMID 27900648. S2CID 45000617.

Etelcalcetide information

and 5 Related for: Etelcalcetide information

Etelcalcetide

Calcimimetic

ATC code H05

Amgen

Peptidomimetic